Terazosin in the treatment of benign prostatic hyperplasia. Terazosin Benign Prostatic Hyperplasia Study Group.
OBJECTIVE
To evaluate the efficacy and tolerability of terazosin, a long-acting selective alpha 1-receptor antagonist, in patients with benign prostatic hyperplasia.


METHODS
Randomized, double-blind, multicenter (eight government and private facilities), placebo-controlled study.


METHODS
Men aged 45 years or older, with qualifying signs and symptoms of benign prostatic hyperplasia (n = 160).


METHODS
Terazosin or placebo once daily, with terazosin dosage titrated to the patient's response. After a 4-week placebo lead-in, 1 to 10 mg of terazosin or placebo was administered for 24 weeks.


METHODS
Decreases in mean Boyarsky scores for obstructive and irritative symptoms and total scores and increases in peak urine flow rate.


RESULTS
Terazosin-treated patients had decreases in Boyarsky obstructive, irritative, and total scores of 3.3 (52%), 1.3 (29%), and 4.6 (42%), respectively, compared with decreases of 0.7 (12%), 0.4 (9%), and 1.1 (11%), respectively, in the placebo group (P < .05). Peak urine flow increased by a mean of 2.6 mL/s (30%) in terazosin-treated patients and 1.2 mL/s (14%) in placebo-treated patients (P < or = .05). Adverse events that differed significantly in the two groups were dizziness (19% in the terazosin group vs 5% in the placebo group) and urinary tract infection (1% in the terazosin group vs 10% in the placebo group).


CONCLUSIONS
These results suggest that terazosin given once daily in doses up to 10 mg alleviates symptoms and improves peak urine flow rate in men with benign prostatic hyperplasia and has an acceptable adverse event profile.
Brawer
M K
MK
Section of Urology, Veterans Affairs Medical Center, Seattle, WA 98108.
Adams
G
G
Epstein
H
H
D000317:Adrenergic alpha-Antagonists / Q000009:adverse effects / Q000627:therapeutic use*; D004311:Double-Blind Method; D006801:Humans; D008297:Male; D008875:Middle Aged; D011224:Prazosin / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D011470:Prostatic Hyperplasia / Q000188:drug therapy* / Q000503:physiopathology; D014563:Urodynamics
D000317:Adrenergic alpha-Antagonists; C041226:Terazosin; D011224:Prazosin